Project Grant R44CA265301
- Award Summary The National Cancer Institute awarded Kaiser Foundation Hospitals (Kaiser Permanente) a Cooperative Agreement valued at $1,406,642 under the Cancer Cause and Prevention Research program (CFDA 93.393) to adapt and implement an evidence-based patient navigation intervention for adolescent and young adult (AYA) cancer survivors aged 15-39. The project, initiated September 8, 2025, and scheduled for completion by August 31, 2027, addresses critical gaps in survivorship care for this...
- This Project Grant award from the Agency for Healthcare Research and Quality (AHRQ) under the Research on Healthcare Costs, Quality and Outcomes program (CFDA 93.226) supports a $400,000 randomized trial to evaluate the impact of a "whole person navigation" intervention for adults with multiple chronic conditions. The intervention combines predictive modeling to identify high-risk patients with a navigation strategy to help guide them in accessing social services and overcoming...
- Federal Grant Award Summary Children's Hospital Los Angeles received a $8.47 million Project Grant from the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research program (CFDA 93.393), effective September 10, 2025, through August 31, 2029. The award funds a patient navigation intervention study designed to improve transition success for multiply disadvantaged young adult survivors of childhood cancer (CCS). The primary deliverable is research demonstrating the...
- TIER-Palliative Care Model Development and Implementation Icahn School of Medicine at Mount Sinai received a $755,540 Project Grant from the National Institute of Nursing Research (CFDA 93.361, Nursing Research program) awarded March 1, 2026, with completion targeted for December 31, 2030. The grant funds development and implementation of the TIER-Palliative Care (TIER-PC) model, an innovative population-based care delivery system designed to match evolving patient needs with appropriate...
- This $708,091 federal Project Grant award from the National Cancer Institute (CFDA 93.393 Cancer Cause and Prevention Research) supports the "Algorithm-Enabled Patients Activated in Cancer Care Through Teams (A-PACT)" project. The goal of this 5-year project is to test the effectiveness of the A-PACT intervention, which uses machine learning algorithms to automatically identify high-risk cancer patients who need goals of care conversations. This allows for scalable delivery of...
- Federal Cooperative Agreement Summary The National Cancer Institute (NCI) awarded Medstar Health Research Institute Inc. a Cooperative Agreement valued at $1,351,734 on July 25, 2025, under the Cancer Cause and Prevention Research program (CFDA 93.393) to deliver practical geriatric assessment services in community oncology settings. The primary objective is to increase the implementation and utilization of geriatric assessment protocols among older cancer patients (age 65+) in community-based...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded Massachusetts General Hospital a $1.72M Project Grant under the Cancer Cause and Prevention Research program (CFDA 93.393) effective June 1, 2025, through April 30, 2030. This award funds a randomized controlled trial of TARGET-PC, a five-session palliative care intervention designed to improve end-of-life (EOL) care outcomes for patients with metastatic breast cancer (MBC) and poor prognosis. The study will utilize the EPIC...
- Federal Grant Award Summary Navigation Sciences Inc. received a $225,229 Project Grant award from the National Cancer Institute under the Cancer Detection and Diagnosis Research program (CFDA 93.394) on September 19, 2025, with an ultimate completion date of February 28, 2027. The award supports the development of EndonaviSCI, novel navigation software designed to enhance lung cancer surgical outcomes by accurately localizing small lung nodules and measuring resection margins during...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded a $817,829 Project Grant to Massachusetts General Hospital, effective September 12, 2025 through August 31, 2030, under the Cancer Treatment Research program (CFDA 93.395). The award funds a randomized controlled trial evaluating SMART3RP-Lymphoma, an evidence-based, multicomponent virtual resilience intervention designed to improve quality of life for lymphoma survivors during the early post-treatment period (0-2 years...
- Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded the Regents of the University of Michigan a Project Grant of $682,272 beginning September 1, 2025, and concluding August 31, 2027, under the Cancer Cause and Prevention Research program (CFDA 93.393). The award funds the development and feasibility assessment of a multifaceted electronic health record (EHR)-integrated mobile health intervention designed to reduce hospital readmissions following radical cystectomy...
SURVIVORCARE: A DIGITAL HEALTH SOLUTION TO SUPPORT LONG-TERM CANCER SURVIVORSHIP USING PATIENT NAVIGATION - PROJECT SUMMARY THERE IS A GROWING AND URGENT NEED TO ADDRESS A GAP IN TRANSITIONAL AND FOLLOW-UP CARE FOR LONG-TERM CANCER SURVIVORS SHIFTING FROM ONCOLOGY-BASED TO PRIMARY AND COMMUNITY-BASED CARE. FRONTLINE HEALTH WORKERS SUCH AS PATIENT NAVIGATORS AND COMMUNITY HEALTH WORKERS CAN SUPPORT CANCER SURVIVORS WITH THE TRANSITION FROM ONCOLOGY- BASED TO PRIMARY CARE. THE OVERALL GOAL OF THIS PHASE II SBIR PROJECT IS TO REFINE AND TEST SURVIVORCARE, A MOBILE- /WEB-BASED SYSTEM TO SUPPORT LONG-TERM CANCER SURVIVORSHIP THROUGH PATIENT NAVIGATION FOR LOW-RESOURCE, UNDERSERVED POPULATIONS. FOLLOWING A HUMAN-CENTERED DESIGN APPROACH AND RECOMMENDATIONS AND LEARNINGS FROM PHASE I PILOT WORK, WE WILL DEVELOP AND TEST A FUNCTIONAL WEB/MOBILE APPLICATION EXPRESSLY DESIGNED FOR PATIENT NAVIGATORS AND OTHER FRONTLINE HEALTH WORKERS ASSISTING WITH PATIENT NAVIGATION AND CANCER SURVIVORS THROUGH A CENTRALIZED PLATFORM SUPPORTING NEEDS RELATED TO CANCER SURVIVORSHIP CARE PLANNING. WE WILL ACHIEVE OUR PROJECT GOAL THROUGH 3 SPECIFIC AIMS: - SPECIFIC AIM 1. WE WILL BUILD A FUNCTIONAL PROTOTYPE BASED ON FEEDBACK COLLECTED IN PHASE I. SPECIFICALLY, WE WILL EXPAND THE SCOPE OF OUR PHASE I WORK TO INCLUDE SUPPORT FOR PATIENTS IN EARLY STAGES OF SURVIVORSHIP WITH PREVALENT CANCER TYPES WITH SURVIVORSHIP CARE PLANS AND/OR PATIENT NAVIGATION PROGRAMS SUCH AS COLORECTAL, BREAST, PROSTATE, LUNG, AND HEAD/NECK CANCERS. SPECIFIC AIM 2. WE WILL CONDUCT USABILITY TESTING OF A FUNCTIONAL PROTOTYPE WITH TARGET END USERS (PATIENT NAVIGATORS AND CANCER SURVIVORS) TO VALIDATE CONTENT AND USABILITY. SPECIFIC AIM 3. WE WILL CONDUCT BETA TESTING IN REAL-WORLD CLINICAL SETTINGS WITH TARGET END USERS IN TWO LARGE, URBAN, SAFETY NET HOSPITALS SERVING DIVERSE, LOW-RESOURCE POPULATIONS. RESULTS FROM THIS PROJECT WILL GO TOWARDS FURTHERING RESEARCH AND IMPLEMENTATION EFFORTS IN DEVELOPING TOOLS TO PROMOTE COLLABORATION AND COORDINATION BETWEEN FRONTLINE HEALTH WORKERS, CANCER SURVIVORS, PCPS, AND OTHER CANCER CARE TEAM MEMBERS TO MITIGATE PRONOUNCED HEALTH DISPARITIES IN LONG-TERM CANCER SURVIVORSHIP.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | ($211k) | 2/3/25 | ||
| Not listed | $736.8k | 8/14/22 | ||
| Not listed | $736.8k | 8/14/22 | ||
| Not listed | $0 | 11/24/21 | ||
| Not listed | $0 | 11/24/21 |